PharmaSeq

Home Company News & Events Press Releases 2015 NSF Awards Phase II SBIR Grant to PharmaSeq to Continue Developing a “Radio p-Chip” for Intracellular Sensing

Press Releases

NSF Awards Phase II SBIR Grant to PharmaSeq to Continue Developing a “Radio p-Chip” for Intracellular Sensing

Monmouth Junction, NJ, January 12, 2015. PharmaSeq, Inc., announced today the award of a Phase II Small Business Innovative Research (SBIR) grant from the National Science Foundation to continue development of a “radio p-Chip.” This revolutionary device will be the first microchip with a sensor that can be injected into live cells to transmit information from within without a physical connection.

The radio p-Chip will combine elements of PharmaSeq’s laser light-activated p-Chip, a novel device that transmits the chip’s serial number via radio signals, with enhancements to monitor events by adding a dielectric sensor. The on-board sensor will gather information about real-time physiological conditions in the cell and transmit them along with the ID number identifying the cell itself. The envisioned device will be one part of a system incorporating, in addition to the radio p-Chip, a custom-designed receiver and antenna system, devices to implant the chip into cells and associated firmware and application software. The goal of the work is to design and demonstrate a fully functional ultra-small optical integrated circuit (IC) with an embedded sensor capable of (a) measuring internal characteristics of a cell and (b) transmitting the information and a unique identification number for the cell over a modulated light beam to an outside receiver. Methods used in electronic engineering, semiconductor design and cell biology will be employed.

Dr. Richard G. Morris, CEO of PharmaSeq, Inc., said: “In December 2013, we completed work on the Phase I stage of this work. We demonstrated the ability to add a sensor to the p-Chip with a goal of making it small enough to study intracellular telemetry in Phase II. We were also able to demonstrate placing a p-Chip directly into a living embryo. Phase II of this work will be directed toward reducing the size of the p-Chip and developing highly effective methods to transmit signals. We project that the radio p-Chip will find many uses in studying basic cell physiology, in developing drugs and therapeutics, as well as in education. The availability of a low-cost, tetherless probe will open up new areas of research and create new disciplines in biotechnology.

For further information, please contact Dr. Richard G. Morris, CEO (rmorris@pharmaseq.com), or Dr. Wlodek Mandecki, President, at (732) 355-0100.

PharmaSeq, Inc.
11 Deer Park Drive,
Suite 104 Monmouth Junction, NJ 08852

 


Download as PDF

 

Home Company News & Events Press Releases 2015 NSF Awards Phase II SBIR Grant to PharmaSeq to Continue Developing a “Radio p-Chip” for Intracellular Sensing